Correlation Between Navidea Biopharmaceutica and Cardiff Oncology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Navidea Biopharmaceutica and Cardiff Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Navidea Biopharmaceutica and Cardiff Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Navidea Biopharmaceuticals and Cardiff Oncology, you can compare the effects of market volatilities on Navidea Biopharmaceutica and Cardiff Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Navidea Biopharmaceutica with a short position of Cardiff Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Navidea Biopharmaceutica and Cardiff Oncology.

Diversification Opportunities for Navidea Biopharmaceutica and Cardiff Oncology

-0.41
  Correlation Coefficient

Very good diversification

The 3 months correlation between Navidea and Cardiff is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Navidea Biopharmaceuticals and Cardiff Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cardiff Oncology and Navidea Biopharmaceutica is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Navidea Biopharmaceuticals are associated (or correlated) with Cardiff Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cardiff Oncology has no effect on the direction of Navidea Biopharmaceutica i.e., Navidea Biopharmaceutica and Cardiff Oncology go up and down completely randomly.

Pair Corralation between Navidea Biopharmaceutica and Cardiff Oncology

Given the investment horizon of 90 days Navidea Biopharmaceuticals is expected to under-perform the Cardiff Oncology. But the pink sheet apears to be less risky and, when comparing its historical volatility, Navidea Biopharmaceuticals is 1.55 times less risky than Cardiff Oncology. The pink sheet trades about -0.5 of its potential returns per unit of risk. The Cardiff Oncology is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  149.00  in Cardiff Oncology on September 12, 2024 and sell it today you would earn a total of  229.00  from holding Cardiff Oncology or generate 153.69% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy1.14%
ValuesDaily Returns

Navidea Biopharmaceuticals  vs.  Cardiff Oncology

 Performance 
       Timeline  
Navidea Biopharmaceutica 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Navidea Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Navidea Biopharmaceutica is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Cardiff Oncology 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cardiff Oncology are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent fundamental indicators, Cardiff Oncology reported solid returns over the last few months and may actually be approaching a breakup point.

Navidea Biopharmaceutica and Cardiff Oncology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Navidea Biopharmaceutica and Cardiff Oncology

The main advantage of trading using opposite Navidea Biopharmaceutica and Cardiff Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Navidea Biopharmaceutica position performs unexpectedly, Cardiff Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiff Oncology will offset losses from the drop in Cardiff Oncology's long position.
The idea behind Navidea Biopharmaceuticals and Cardiff Oncology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Technical Analysis
Check basic technical indicators and analysis based on most latest market data